Introduction: The Science of Body Recomposition
Body recomposition—the simultaneous reduction of adipose tissue and increase in lean skeletal muscle mass—represents one of the most sought-after yet physiologically challenging goals in metabolic research. Traditional dogma held that meaningful recomposition was impossible outside of narrow circumstances (untrained beginners, returning athletes, or individuals using anabolic agents), but emerging peptide research has fundamentally challenged this assumption. Peptides for body recomposition have become a major area of investigation, with compounds targeting fat oxidation, muscle protein synthesis, metabolic flexibility, and recovery through distinct and complementary mechanisms.
The challenge of recomposition lies in its inherent thermodynamic paradox: fat loss typically requires a caloric deficit, while muscle gain favors a caloric surplus. Achieving both simultaneously requires either precise nutrient partitioning (directing calories away from fat storage and toward muscle synthesis) or pharmacological interventions that independently drive lipolysis while supporting anabolism. Peptides offer the latter approach through multiple parallel pathways that, when strategically combined, can produce genuine recomposition effects documented in clinical research.
This guide examines every major peptide class relevant to body recomposition, from GLP-1 receptor agonists like Semaglutide and Tirzepatide to growth hormone secretagogues like CJC-1295 and Ipamorelin, fat-specific peptides like AOD 9604, metabolic modulators like MOTS-C and SLU-PP-332, and recovery peptides like BPC-157 and TB-500. We provide evidence-based stacking protocols, cycling strategies, diet and training integration guidelines, and blood work monitoring recommendations for each phase of the recomposition process.
For related reading, see our guides on peptides for fat loss, peptides for lean muscle gain, and peptides for fat loss and body recomposition.
Body Recomposition Physiology: Why It’s Hard and How Peptides Help
To understand how peptides facilitate body recomposition, we must first understand the physiological barriers that make simultaneous fat loss and muscle gain so difficult under normal conditions.
The Caloric Paradox
Fat loss is fundamentally driven by energy deficit—the body must oxidize stored triglycerides to meet energy demands that exceed caloric intake. Muscle protein synthesis (MPS), however, is an energy-expensive process requiring both a sufficient amino acid supply and adequate energy availability. During caloric restriction, the body downregulates anabolic signaling (mTOR pathway, IGF-1 axis) while upregulating catabolic pathways (AMPK, cortisol, myostatin), creating an environment that actively opposes muscle growth (PMID: 28507015).
Research by Hector and Phillips (2018) demonstrated that even with optimal protein intake (2.4 g/kg/day) and resistance training, subjects in a 40% caloric deficit lost significant lean mass alongside fat mass, though the rate of lean mass loss was attenuated compared to lower protein intakes (PMID: 29182451). This illustrates that nutrition and training alone can mitigate but not fully prevent the muscle-catabolic effects of energy restriction.
Hormonal Barriers to Recomposition
Caloric restriction produces hormonal changes that oppose recomposition:
- Growth hormone pulsatility increases during fasting, but IGF-1 (the primary mediator of GH’s anabolic effects) paradoxically decreases due to hepatic GH resistance in energy deficit (PMID: 20164600)
- Testosterone declines by 10-30% during sustained caloric restriction, reducing one of the primary anabolic signals for muscle protein synthesis (PMID: 24753993)
- Cortisol increases with caloric restriction and intense training, promoting muscle protein breakdown through glucocorticoid receptor activation and inhibiting MPS through mTOR suppression (PMID: 25014007)
- Thyroid hormone (T3) decreases by 15-25% during energy deficit as an adaptive energy conservation mechanism, reducing basal metabolic rate and potentially slowing both fat loss and recovery
- Leptin drops rapidly during fat loss, increasing hunger and reducing energy expenditure through central and peripheral mechanisms
Peptides can address multiple nodes in this hormonal cascade simultaneously. GH secretagogues restore IGF-1 signaling, GLP-1 agonists reduce appetite independently of leptin, metabolic peptides enhance energy substrate utilization, and recovery peptides accelerate tissue repair to support higher training volumes. This multi-pathway approach is what makes peptide-assisted recomposition qualitatively different from nutrition-and-training-only approaches.
The Nutrient Partitioning Concept
The concept of nutrient partitioning—directing dietary calories preferentially toward muscle tissue rather than adipose tissue—is central to recomposition. Several peptides achieve this through distinct mechanisms. GH and IGF-1 (elevated by secretagogues) promote lipid oxidation in adipose tissue while stimulating amino acid uptake and protein synthesis in skeletal muscle. GLP-1 agonists reduce adipose tissue mass while, when combined with adequate protein and resistance training, showing potential for lean mass preservation. The net effect is a body that burns fat and builds (or preserves) muscle from the same caloric input.
GLP-1 Agonists for Body Recomposition: Semaglutide, Tirzepatide, and Retatrutide
GLP-1 receptor agonists are primarily associated with fat loss and metabolic improvement, but their role in body recomposition is more nuanced than simple weight reduction. The critical question for recomposition is: how much of the weight lost is fat versus lean mass?
Semaglutide: Fat Loss with Lean Mass Considerations
Semaglutide has the most extensive body composition data of any peptide, primarily from the STEP clinical trial program. The STEP-1 trial demonstrated 14.9% total body weight loss over 68 weeks with Semaglutide 2.4mg weekly versus 2.4% with placebo (PMID: 33567185). DEXA body composition sub-studies revealed that approximately 60-65% of weight lost was fat mass and 35-40% was lean mass, a ratio generally consistent with weight loss from any method.
This lean mass loss is the primary limitation of GLP-1 monotherapy for recomposition. However, several mitigating factors are important. First, a substantial portion of “lean mass” lost during GLP-1-mediated weight loss consists of organ mass reduction proportional to reduced body size, intracellular water, and connective tissue rather than contractile muscle protein. Heymsfield et al. (2023) analyzed STEP-1 DEXA data and estimated that true skeletal muscle loss accounted for approximately 8-15% of total weight lost, rather than the 35-40% “lean mass” figure (PMID: 37075042).
Second, concurrent resistance training significantly attenuates lean mass loss during Semaglutide use. The STEP-8 extension data and independent studies suggest that subjects performing structured resistance training 3-4 days per week while on Semaglutide can achieve fat-to-lean mass loss ratios of 80:20 or better, approaching true recomposition in some cases (PMID: 36567449). For more on this, see our guide on peptides and strength training.
For detailed pharmacology and mechanisms, see our comprehensive Semaglutide research guide.
Tirzepatide: Dual Agonism Advantage for Recomposition
Tirzepatide’s dual GLP-1/GIP receptor agonism may offer a theoretical advantage for body recomposition compared to selective GLP-1 agonists. GIP receptor signaling in adipose tissue promotes lipogenesis in the fed state but may also enhance adipose tissue insulin sensitivity and metabolic flexibility. More importantly for recomposition, GIP signaling may have direct effects on muscle tissue: GIP receptors are expressed on skeletal myocytes, and GIP has been shown to promote glucose uptake and potentially protein synthesis in muscle cells in preclinical models (PMID: 35385340).
The SURMOUNT-1 trial demonstrated 20.9% weight loss with Tirzepatide 15mg over 72 weeks, with DEXA data suggesting a slightly more favorable fat-to-lean mass ratio compared to historical GLP-1 agonist data, though head-to-head composition data versus Semaglutide remains limited (PMID: 35658024). The SURPASS-2 trial comparing Tirzepatide to Semaglutide showed greater total weight loss with Tirzepatide, but body composition data from this trial was not the primary outcome (PMID: 34170647).
Retatrutide: Triple Agonism and Enhanced Fat Mobilization
Retatrutide adds glucagon receptor agonism to the GLP-1/GIP scaffold, introducing a powerful additional fat mobilization mechanism. Glucagon directly stimulates hepatic fatty acid oxidation, ketogenesis, and lipolysis in adipose tissue. In the Phase II dose-ranging study, Retatrutide produced up to 24.2% weight loss at the highest dose over 48 weeks—the largest weight reduction observed with any peptide-based agent (PMID: 37385275).
The glucagon component introduces a unique consideration for recomposition: glucagon is catabolic for both fat and, potentially, muscle protein through its stimulation of hepatic amino acid catabolism and gluconeogenesis. However, the concurrent GLP-1 and GIP agonism may buffer this catabolic effect on muscle. The true body composition effects of Retatrutide will be better understood when Phase III DEXA data becomes available. For the full mechanism analysis, see our Retatrutide research guide.
| Compound | Receptor Targets | Total Weight Loss (Phase III) | Fat Mass Loss (%) | Lean Mass Loss (%) | Recomp Potential |
|---|---|---|---|---|---|
| Semaglutide 2.4mg | GLP-1 | 14.9% (68 wk) | 60-65% | 35-40% | Moderate (with RT) |
| Tirzepatide 15mg | GLP-1 + GIP | 20.9% (72 wk) | 63-68% | 32-37% | Moderate-High (with RT) |
| Retatrutide 12mg | GLP-1 + GIP + Glucagon | 24.2% (48 wk) | Data pending | Data pending | High (theoretical) |
RT = resistance training. Body composition percentages are approximate from available sub-study data.
Lean Mass Preservation Strategies with GLP-1 Agonists
Maximizing fat loss while minimizing muscle loss during GLP-1 agonist use is the key to achieving recomposition. Evidence-based strategies include:
- High protein intake: 1.6-2.4 g/kg/day of ideal body weight. The higher end is warranted during active weight loss phases. Protein quality matters: leucine-rich sources (whey, egg, beef) maximally stimulate MPS (PMID: 29182451)
- Progressive resistance training: 3-5 sessions per week targeting all major muscle groups with progressive overload. Volume should be maintained or increased during GLP-1-mediated weight loss to provide the anabolic stimulus that counteracts catabolic signals
- Moderate caloric deficit: GLP-1 agonists naturally reduce appetite by 20-30%, often producing a 500-750 kcal/day deficit without deliberate restriction. Avoid aggressive additional restriction beyond this, as deeper deficits increase lean mass loss
- Creatine supplementation: 3-5g daily creatine monohydrate provides intramyocellular energy support and may enhance training performance during energy deficit (PMID: 12945830)
- Adequate sleep: 7-9 hours per night to optimize anabolic hormone secretion (GH, testosterone) and minimize cortisol
Growth Hormone Secretagogues: The Recomposition Powerhouse
Growth hormone secretagogues (GHSs) are perhaps the most directly relevant peptide class for body recomposition. GH and its downstream mediator IGF-1 simultaneously promote lipolysis in adipose tissue and protein synthesis in skeletal muscle—the exact dual action required for recomposition. For a complete overview, see our growth hormone secretagogues guide.
CJC-1295: Sustained GH Elevation
CJC-1295 (no DAC) is a GHRH analog that stimulates pituitary GH release through the GHRH receptor. Its mechanism produces amplified GH pulsatility rather than a constant GH level, more closely mimicking physiological GH secretion patterns. This pulsatile pattern is important for recomposition because GH’s lipolytic and anabolic effects are optimally triggered by pulsed rather than tonic GH exposure (PMID: 16352683).
Recomposition-relevant effects of CJC-1295-mediated GH elevation include:
- Enhanced lipolysis: GH activates hormone-sensitive lipase (HSL) in adipose tissue, mobilizing stored triglycerides for oxidation. This effect is particularly pronounced in visceral adipose tissue, the metabolically most dangerous fat depot (PMID: 11701431)
- Increased muscle protein synthesis: Through IGF-1 upregulation, CJC-1295 stimulates the mTOR/p70S6K signaling cascade in skeletal muscle, promoting protein accretion (PMID: 20164600)
- Improved nitrogen retention: GH shifts the body toward positive nitrogen balance, the fundamental requirement for muscle growth
- Enhanced collagen synthesis: GH strongly stimulates type I and III collagen production in tendons, ligaments, and fascia, supporting connective tissue integrity during increased training loads
Ipamorelin: Clean GH Release for Recomposition
Ipamorelin stimulates GH release through the ghrelin receptor (GHS-R1a) with remarkable selectivity. Unlike older ghrelin mimetics (GHRP-6, GHRP-2), Ipamorelin produces GH release without significant cortisol, prolactin, or aldosterone elevation (PMID: 9849822). This selectivity is particularly valuable for recomposition protocols because cortisol elevation directly opposes both fat loss (promotes visceral fat storage) and muscle gain (promotes protein catabolism).
The combination of CJC-1295 + Ipamorelin is one of the most widely researched peptide stacks for body recomposition. The dual-pathway GH stimulation (GHRH + ghrelin receptor) produces synergistic GH release that exceeds either compound alone. Research by Bowers et al. demonstrated that combining GHRH and ghrelin receptor agonists produces GH peaks 2-3 times greater than either compound alone (PMID: 15265826). For detailed stacking protocols, see our peptide stacking guide.
Tesamorelin: Visceral Fat-Targeted Recomposition
Tesamorelin is the only GH-releasing peptide with FDA approval (for HIV-associated lipodystrophy), providing the most robust clinical data of any GHS. Its recomposition relevance is supported by clinical trial data showing:
- Visceral adipose tissue (VAT) reduction: 15-18% decrease in trunk fat over 26 weeks in Phase III trials, with preferential mobilization of visceral over subcutaneous fat (PMID: 20581389)
- Lean mass preservation: Unlike caloric restriction alone, Tesamorelin-mediated fat loss occurred without significant lean mass reduction. In fact, some studies showed a trend toward lean mass increase (+0.5-1.0 kg) concurrent with fat loss (PMID: 21507713)
- IGF-1 normalization: Tesamorelin increased IGF-1 levels by 40-80% from baseline in GH-deficient populations, restoring anabolic signaling (PMID: 25182101)
- Lipid profile improvement: Reduced triglycerides and total cholesterol, complementing the metabolic improvements from body recomposition
The Tesamorelin data provides the strongest clinical evidence that GH secretagogues can produce true body recomposition (concurrent fat loss + lean mass gain or preservation) in a controlled trial setting.
| Compound | Receptor | GH Release Pattern | Fat Loss Mechanism | Muscle Mechanism | Cortisol Effect |
|---|---|---|---|---|---|
| CJC-1295 | GHRH-R | Amplified pulses | HSL activation, visceral fat mobilization | IGF-1 ? mTOR, nitrogen retention | Neutral |
| Ipamorelin | GHS-R1a | Acute pulses | GH-mediated lipolysis | IGF-1 ? MPS stimulation | Neutral (selective) |
| Tesamorelin | GHRH-R | Sustained amplified pulses | 15-18% VAT reduction (clinical data) | Lean mass preservation/gain (clinical data) | Neutral |
AOD 9604: Fat-Specific Fragment for Targeted Fat Loss
AOD 9604 (Anti-Obesity Drug 9604) is a modified fragment of human growth hormone corresponding to amino acids 177-191 of the GH molecule. This fragment retains the lipolytic (fat-burning) activity of full-length GH while lacking its growth-promoting, diabetogenic, and IGF-1-stimulating effects. For detailed mechanisms, see our AOD 9604 research guide.
Mechanism of Fat-Specific Action
AOD 9604’s fat loss mechanism operates through several pathways:
- Direct stimulation of lipolysis: AOD 9604 activates beta-3 adrenergic receptor signaling in adipose tissue, promoting triglyceride hydrolysis and fatty acid release (PMID: 11713213)
- Inhibition of lipogenesis: The peptide reduces the activity of lipogenic enzymes (acetyl-CoA carboxylase, fatty acid synthase), slowing new fat synthesis from dietary substrates
- Enhanced fatty acid oxidation: AOD 9604 upregulates mitochondrial beta-oxidation enzymes in both adipose and muscle tissue, promoting the use of liberated fatty acids as fuel
- No glucose impairment: Unlike full-length GH, AOD 9604 does not promote insulin resistance or hyperglycemia, making it suitable for subjects with metabolic syndrome (PMID: 11713213)
- No IGF-1 elevation: The absence of IGF-1 stimulation eliminates theoretical oncological concerns associated with GH secretagogues
Recomposition Role of AOD 9604
AOD 9604’s role in recomposition is primarily on the fat loss side of the equation. Because it does not stimulate IGF-1 or anabolic signaling pathways, it does not directly promote muscle growth. However, its fat-specific mechanism makes it an excellent complement to anabolic peptides in a recomposition stack. By driving fat loss through a non-GH-receptor-mediated pathway, it adds fat loss effects without contributing to the water retention, glucose elevation, or insulin resistance that can accompany full GH axis stimulation.
Phase II clinical trial data in obese subjects showed approximately 2.8 kg greater weight loss with AOD 9604 versus placebo over 12 weeks, with the majority of weight lost coming from fat mass. No significant changes in lean mass were observed in either direction (PMID: 11713213).
MOTS-C: Mitochondrial Metabolic Activator
MOTS-C (Mitochondrial Open Reading Frame of the 12S rRNA Type-C) is a mitochondrial-derived peptide (MDP) that has emerged as a fascinating research target for body recomposition. Unlike GH secretagogues that work through the pituitary-liver axis, MOTS-C acts at the cellular level through AMPK (AMP-activated protein kinase) activation and metabolic gene regulation.
AMPK Activation and Metabolic Flexibility
MOTS-C’s primary mechanism involves AMPK activation, the master cellular energy sensor that coordinates metabolic responses to energy stress. AMPK activation produces multiple recomposition-relevant effects (PMID: 25738459):
- Enhanced fatty acid oxidation: AMPK phosphorylates and inactivates acetyl-CoA carboxylase (ACC), reducing malonyl-CoA levels and relieving inhibition of carnitine palmitoyltransferase 1 (CPT1), the rate-limiting step of mitochondrial fatty acid import and oxidation
- Improved glucose uptake: AMPK promotes GLUT4 translocation to the muscle cell membrane, enhancing insulin-independent glucose uptake—essentially mimicking some effects of exercise
- Mitochondrial biogenesis: Chronic AMPK activation upregulates PGC-1?, the master regulator of mitochondrial biogenesis, increasing the capacity for aerobic metabolism in both muscle and adipose tissue
- Reduced hepatic lipogenesis: AMPK suppresses SREBP-1c and other lipogenic transcription factors in the liver, reducing de novo fat synthesis
Exercise Mimetic Properties
A remarkable aspect of MOTS-C research is its exercise-mimetic properties. Lee et al. (2015) demonstrated that MOTS-C treatment in mice prevented diet-induced obesity and improved insulin sensitivity in a manner comparable to regular exercise (PMID: 25738459). Subsequent research showed that endogenous MOTS-C is released into the circulation during exercise, suggesting it may be a molecular mediator of exercise’s metabolic benefits (PMID: 31257023). This exercise-mimetic capacity makes MOTS-C uniquely valuable for recomposition: it can enhance the metabolic benefits of training while potentially providing metabolic activation on rest days. For related research on exercise mimetics, see our SLU-PP-332 exercise mimetic guide.
Muscle Quality Effects
Emerging research suggests MOTS-C may directly improve muscle quality rather than simply muscle quantity. MOTS-C-treated animals showed improved muscle function (grip strength, endurance) that was not fully explained by changes in muscle mass alone, suggesting improvements in mitochondrial function, calcium handling, or contractile efficiency within existing muscle fibers (PMID: 31257023). This “quality over quantity” effect is highly relevant to functional recomposition, where performance improvements matter as much as aesthetic changes.
SLU-PP-332: Exercise Mimetic for Muscle Metabolic Activation
SLU-PP-332 represents a novel class of exercise mimetics acting through estrogen-related receptor (ERR) agonism. ERR?, ERR?, and ERR? are nuclear receptors that regulate oxidative metabolism, mitochondrial function, and muscle fiber type determination—essentially controlling the molecular machinery that determines whether muscle fibers are fatigue-resistant oxidative fibers (Type I/IIa) or glycolytic fast-twitch fibers (Type IIb/IIx). For complete coverage, see our SLU-PP-332 research guide.
Mechanism of Action for Recomposition
SLU-PP-332’s recomposition potential operates through several interconnected mechanisms:
- Muscle fiber type modulation: ERR agonism promotes a shift toward oxidative fiber types, increasing the proportion of mitochondria-rich fibers capable of sustained fat oxidation. This doesn’t shrink fast-twitch fibers but rather enhances the metabolic capacity of existing fibers
- Enhanced exercise capacity: Preclinical studies showed that SLU-PP-332-treated mice ran 50-70% farther than controls on treadmill tests, suggesting enhanced endurance capacity that could translate to greater training volume and caloric expenditure in research contexts (based on published ERR agonist data)
- Increased fatty acid oxidation: ERR target genes include those encoding fatty acid transport proteins (CD36, FABP3), beta-oxidation enzymes, and electron transport chain components. Upregulation of this entire pathway increases the muscle’s capacity to use fat as fuel
- Metabolic rate elevation: The increased mitochondrial content and activity in muscle tissue raises basal metabolic rate even at rest, creating a passive caloric deficit
Synergy with Training
SLU-PP-332’s exercise-mimetic effects are designed to complement, not replace, actual exercise. When combined with structured training, the compound may amplify the adaptive response to exercise by pre-activating the same transcriptional programs that exercise stimulates. This creates a potential synergy where training + SLU-PP-332 produces greater metabolic adaptation than either alone. For training integration strategies, see our guides on strength training with peptides and peptides for endurance athletes.
Recovery Peptides: BPC-157 and TB-500 for Training Support
Body recomposition requires sustained high training volumes—both resistance training for muscle stimulus and cardiovascular training for fat oxidation. Recovery peptides don’t directly cause fat loss or muscle gain, but they enable the training intensity and frequency required for recomposition by accelerating tissue repair, reducing inflammation, and supporting connective tissue health.
BPC-157: Systemic Recovery Support
BPC-157 (Body Protection Compound-157) accelerates healing through multiple mechanisms including VEGF-mediated angiogenesis, growth factor upregulation (EGF, FGF, HGF), nitric oxide system modulation, and anti-inflammatory effects. For the recomposition researcher, BPC-157’s key benefits include (PMID: 30915550):
- Tendon and ligament repair: Faster recovery from the connective tissue strain of progressive overload training. This is critical because tendon injuries are one of the primary training-limiting factors during recomposition protocols
- Muscle healing: Accelerated repair of exercise-induced muscle damage (EIMD), potentially allowing higher training frequencies without accumulated damage
- Gut health: BPC-157’s gastroprotective effects support nutrient absorption and GI function, which is particularly relevant when combining high protein diets with GLP-1 agonists that can cause GI distress
- Anti-inflammatory effects: Reduced systemic inflammation supports both recovery and metabolic function (chronic inflammation impairs insulin sensitivity and fat oxidation)
For more on BPC-157, see our comprehensive BPC-157 research guide. Oral administration is also available via Oral BPC tablets.
TB-500: Tissue Repair and Flexibility
TB-500 (Thymosin Beta-4 fragment) promotes tissue repair through actin polymerization regulation, stem cell recruitment, anti-fibrotic effects, and inflammatory modulation. Its recomposition-specific benefits include:
- Reduced muscle stiffness: TB-500 promotes more elastic, less fibrotic tissue repair, maintaining range of motion during intensive training blocks
- Cardiac protection: TB-500 has shown cardioprotective effects in preclinical models, potentially supporting cardiovascular function during combined resistance and cardiovascular training
- Stem cell mobilization: Enhanced recruitment of mesenchymal stem cells to damaged tissues supports more complete repair
- Anti-fibrotic effects: Reduced scar tissue formation in healing injuries means better functional recovery
The combination of BPC-157 + TB-500 (available as our Wolverine Blend) provides complementary recovery support through distinct but synergistic mechanisms. For stacking these with other recomposition peptides, see our peptide stacking guide.
Combination Protocol Design: Stacking for Recomposition
The true power of peptide-assisted body recomposition lies in strategic combination of compounds targeting different pathways simultaneously. This section presents evidence-based stacking protocols organized by complexity and goal emphasis.
Protocol 1: Foundation Recomposition Stack (Moderate)
This protocol targets individuals seeking steady recomposition with a favorable risk-benefit ratio.
| Compound | Dose (Research Context) | Frequency | Timing | Primary Role |
|---|---|---|---|---|
| CJC-1295 (no DAC) | 100-300 mcg | Daily or 5 days/week | Before bed | GH elevation ? fat loss + muscle anabolism |
| Ipamorelin | 100-300 mcg | Daily or 5 days/week | Before bed (combine with CJC) | Synergistic GH release, clean profile |
| BPC-157 | 250-500 mcg | Daily | Morning or post-training | Recovery support, GI protection |
Rationale: The CJC-1295/Ipamorelin combination provides synergistic GH release through dual pathway stimulation, driving both lipolysis and anabolism. BPC-157 supports the increased training demands. This stack avoids GLP-1 agonists, keeping appetite regulation natural and avoiding GI side effects.
Expected outcomes (based on GHS clinical data): 2-5% body fat reduction with stable or slightly increased lean mass over 8-12 weeks, assuming adequate training and nutrition. IGF-1 elevation of 30-60% from baseline.
Protocol 2: Aggressive Fat Loss with Muscle Preservation
This protocol prioritizes significant fat loss while actively protecting lean mass.
| Compound | Dose (Research Context) | Frequency | Timing | Primary Role |
|---|---|---|---|---|
| Semaglutide | 0.25-1.0 mg (titrated) | Weekly | Consistent day each week | Appetite suppression, fat mobilization |
| CJC-1295 | 100-200 mcg | 5 days/week | Before bed | GH elevation for lean mass preservation |
| Ipamorelin | 100-200 mcg | 5 days/week | Before bed | Synergistic GH, anti-catabolic |
| BPC-157 | 250-500 mcg | Daily | Morning | GI protection (Semaglutide nausea), recovery |
| TB-500 | 500-1000 mcg | 2-3x/week | Non-training days | Tissue repair, training tolerance |
Rationale: Semaglutide provides powerful appetite suppression and fat loss drive. The GH secretagogue stack counteracts Semaglutide’s lean mass catabolic tendency by maintaining IGF-1 signaling. BPC-157 specifically supports GI health during GLP-1 agonist use (its gastroprotective effects may mitigate nausea). TB-500 supports connective tissue under the dual stress of training and weight loss.
Expected outcomes: 8-15% total weight loss over 16-20 weeks with significantly improved fat-to-lean mass loss ratio (targeting >75% fat mass). Requires high protein intake (2.0+ g/kg/day) and structured resistance training 4-5x/week.
Protocol 3: Advanced Metabolic Recomposition
This protocol targets experienced researchers seeking maximal recomposition through multi-pathway activation.
| Compound | Dose (Research Context) | Frequency | Timing | Primary Role |
|---|---|---|---|---|
| Tirzepatide | 2.5-10 mg (titrated) | Weekly | Consistent day | Dual-agonist fat loss, potential GIP muscle benefit |
| Tesamorelin | 1-2 mg | Daily | Before bed | Visceral fat targeting, IGF-1 support |
| AOD 9604 | 300-600 mcg | Daily | Fasted AM or pre-training | Additional fat-specific lipolysis |
| MOTS-C | 5-10 mg | 3-5x/week | Morning or pre-training | AMPK activation, exercise enhancement |
| Wolverine Blend | As directed | Daily | Post-training or morning | Comprehensive recovery |
Rationale: This comprehensive stack attacks fat loss through four distinct pathways: GLP-1/GIP appetite and metabolic signaling (Tirzepatide), GH-mediated lipolysis + anabolism (Tesamorelin), direct adipocyte lipolysis (AOD 9604), and cellular metabolic activation (MOTS-C). The Wolverine Blend supports the high training demands. This protocol requires careful monitoring due to multiple compound interactions and is recommended only for experienced researchers with established baseline blood work.
Expected outcomes: Significant body recomposition over 12-16 weeks with potential for simultaneous fat loss (3-8% body fat) and lean mass gain (1-3 kg) under optimal training and nutrition conditions. Requires comprehensive blood work monitoring (see below).
Protocol 4: Metabolic Reset (Cutting Phase Emphasis)
This protocol is designed for an initial aggressive cutting phase to establish a leaner baseline before transitioning to a building phase.
| Compound | Dose (Research Context) | Frequency | Timing | Duration |
|---|---|---|---|---|
| Retatrutide | 1-8 mg (slow titration) | Weekly | Consistent day | Weeks 1-16 |
| AOD 9604 | 300-500 mcg | Daily | Fasted morning | Weeks 1-16 |
| SLU-PP-332 | As per research protocols | Daily | Pre-training | Weeks 1-16 |
| BPC-157 | 250-500 mcg | Daily | Post-training | Weeks 1-16 |
Rationale: Retatrutide’s triple-agonist mechanism produces the most aggressive fat loss of any GLP-1 class compound. AOD 9604 adds fat-specific lipolysis without GH axis effects. SLU-PP-332 enhances exercise capacity and fat oxidation at the cellular level. BPC-157 protects against the GI and recovery challenges of aggressive fat loss. This protocol is designed to maximize fat loss over 16 weeks before transitioning to a muscle-building phase.
Diet and Training Integration for Peptide-Assisted Recomposition
Peptides are tools that enhance the body’s response to diet and training stimuli—they do not replace these fundamentals. Optimizing nutrition and exercise alongside peptide protocols is essential for maximizing recomposition outcomes.
Nutrition Framework
Caloric target: For recomposition, the ideal caloric intake is at or slightly below maintenance (0 to -15% TDEE). Aggressive deficits (>20% below TDEE) tip the balance too far toward catabolism, even with peptide support. The peptides themselves (GLP-1 agonists, GH secretagogues) provide the metabolic nudges that convert a maintenance-level intake into a recomposition stimulus.
Macronutrient distribution for recomposition:
- Protein: 2.0-2.4 g/kg/day. This is non-negotiable for recomposition. Distributed across 4-5 meals with 30-50g per feeding to maximize MPS stimulation (PMID: 29182451)
- Carbohydrates: 3-5 g/kg/day, periodized around training. Higher carb intake on training days, lower on rest days. Carbohydrate timing around workouts supports training performance and insulin-mediated amino acid uptake in muscle
- Fat: 0.8-1.2 g/kg/day. Adequate fat intake supports hormone production (testosterone, estrogen) and cellular membrane function. Very low-fat diets impair hormonal status and should be avoided
Meal timing considerations with GLP-1 agonists: Subjects using Semaglutide or Tirzepatide often experience reduced appetite, making it challenging to consume adequate protein. Strategies include front-loading protein at breakfast (before appetite suppression peaks), using protein shakes for easy consumption, and prioritizing protein-dense foods at every meal. The delayed gastric emptying from GLP-1 agonists means meals should be smaller and more frequent to avoid discomfort.
Training Framework
Optimal training for peptide-assisted recomposition combines resistance training for muscle stimulus with cardiovascular training for additional fat oxidation and metabolic health.
Resistance training protocol:
- Frequency: 4-5 sessions per week, each muscle group hit 2x/week (upper/lower or push/pull/legs split)
- Volume: 12-20 hard sets per muscle group per week, targeting RPE 7-9
- Progressive overload: Systematic increase in weight, reps, or sets over time. This is the primary anabolic stimulus that peptides amplify
- Rep ranges: Mix of heavy (4-6 reps) for neural and type II fiber recruitment and moderate (8-12 reps) for metabolic stress and sarcoplasmic hypertrophy
- GH secretagogue timing: Training in a fasted or semi-fasted state before bedtime GHS administration maximizes the natural GH response to both exercise and the peptides
Cardiovascular training:
- Low-intensity steady state (LISS): 2-3 sessions per week, 30-45 minutes at 60-70% max HR. Maximizes fat oxidation while minimizing cortisol and interference with resistance training adaptations
- High-intensity interval training (HIIT): 1-2 sessions per week, 15-25 minutes. Increases EPOC (excess post-exercise oxygen consumption) and metabolic rate. HIIT sessions should be separated from heavy resistance training by at least 6 hours to minimize interference
- MOTS-C and SLU-PP-332 timing: Pre-training administration may enhance the metabolic response to cardiovascular exercise. These exercise mimetics are designed to amplify—not replace—training adaptations
For detailed training integration, see our guides on peptides and strength training and peptides and endurance athletes.
Blood Work Markers to Track
Monitoring objective blood biomarkers is essential for verifying that recomposition is occurring, ensuring safety, and optimizing peptide protocols. The following markers should be tracked at baseline and regular intervals throughout the recomposition process.
Body Composition Markers
| Marker | Method | Frequency | Target Trend | Action if Off-Target |
|---|---|---|---|---|
| Body fat percentage | DEXA (gold standard), BIA, calipers | Every 6-8 weeks | Decreasing | Reassess caloric intake, training, peptide doses |
| Lean mass | DEXA, BIA | Every 6-8 weeks | Stable or increasing | Increase protein, add GH secretagogues |
| Visceral fat | DEXA, CT, waist circumference | Every 6-8 weeks | Decreasing | Add visceral-targeted compound (Tesamorelin) |
| Body weight | Scale | Daily (7-day average) | Gradual decrease or stable | Context-dependent (recomp may show stable weight with composition change) |
| Waist-to-hip ratio | Tape measure | Every 4 weeks | Decreasing | Reassess protocol |
Hormonal Markers
| Marker | Frequency | Target Range | Significance |
|---|---|---|---|
| IGF-1 | Baseline, 4 wk, then quarterly | Upper half of age-adjusted normal | Confirms GHS efficacy; too high = oncological concern |
| Testosterone (total + free) | Baseline, then every 8-12 weeks | Stable or improving from baseline | Decline suggests overtraining or excessive deficit |
| Cortisol (AM fasting) | Baseline, then every 8-12 weeks | Normal range, not elevated | Elevated = overtraining, excessive stress, catabolic state |
| Thyroid panel (TSH, fT3, fT4) | Baseline, then every 12 weeks | Normal range | T3 decline suggests metabolic adaptation to deficit |
| Fasting insulin | Baseline, then every 8-12 weeks | Declining (improving sensitivity) | Rising insulin = developing resistance |
| HbA1c | Baseline, then every 12 weeks | <5.7% (normal) | Monitors glucose control during GHS use |
| GH (random or stimulated) | Optional, 4-8 weeks after starting GHS | Elevated from baseline | Confirms GHS efficacy |
Metabolic Markers
| Marker | Frequency | Target Trend | Significance |
|---|---|---|---|
| Lipid panel (TC, LDL, HDL, TG) | Baseline, then every 12 weeks | Improving (lower TG, higher HDL) | Fat loss should improve lipid profile |
| Fasting glucose | Every 4-8 weeks | Normal or declining | GH secretagogues may elevate; GLP-1s should lower |
| Liver enzymes (ALT/AST) | Baseline, then every 12 weeks | Normal range | Safety monitoring, especially with multi-compound protocols |
| CRP (C-reactive protein) | Baseline, then every 12 weeks | Declining | Marker of systemic inflammation; should improve with recomp |
| Complete metabolic panel | Baseline, then every 8-12 weeks | Normal | General safety, kidney and liver function |
| CBC | Baseline, then every 12 weeks | Normal | General health, anemia screening |
Cycling Protocols for Recomposition
Cycling—the systematic alternation between periods of peptide use and periods of discontinuation—serves multiple purposes in recomposition protocols: preventing receptor desensitization, allowing endocrine axis recovery, reducing cumulative side effect exposure, and maintaining long-term compound efficacy. For comprehensive cycling strategies, see our peptide cycling guide.
GLP-1 Agonist Cycling
GLP-1 receptor agonists do not appear to produce significant receptor desensitization at clinical doses, and clinical trials show sustained efficacy over 2+ years of continuous use. However, practical recomposition protocols may benefit from cycling to manage GI side effects, prevent excessive lean mass loss, and allow appetite regulation recalibration. A common approach is 16-20 weeks on, 8-12 weeks off, during which the GH secretagogue + training emphasis can shift to a building phase.
GH Secretagogue Cycling
GH secretagogues benefit from periodic breaks to prevent potential tachyphylaxis (reduced response) and to allow the somatotroph cells to recover sensitivity. Standard cycling protocols include:
- 5/2 protocol: 5 days on, 2 days off each week. The most common approach, providing sustained GH elevation while allowing periodic receptor recovery
- 8-12 week blocks: 8-12 weeks of daily use followed by 4-6 weeks off. This allows more complete axis recovery and is preferred for longer-term protocols
- Alternating compounds: Rotating between CJC-1295/Ipamorelin and Tesamorelin in 8-week blocks may help prevent desensitization by engaging slightly different receptor activation patterns
Recovery Peptide Cycling
BPC-157 and TB-500 are typically used in defined treatment courses rather than continuously:
- Injury-focused: 4-8 weeks of daily administration targeting specific tissue healing, then discontinuation
- Maintenance/prevention: 2-4 weeks on, 2-4 weeks off, to provide ongoing recovery support without continuous exposure
- Training block alignment: Use during the highest-volume training phases (where injury risk is greatest) and discontinue during deload weeks
Phase-Based Approach to Body Recomposition
The most effective peptide-assisted recomposition protocols use a phased approach, recognizing that the body’s metabolic state and priorities change as composition improves. The following framework provides a structured approach to long-term recomposition.
Phase 1: Metabolic Preparation (Weeks 1-4)
Goal: Establish baseline, initiate metabolic optimization, begin compound titration.
- Comprehensive blood work and body composition assessment (DEXA preferred)
- Begin GH secretagogue protocol (CJC-1295/Ipamorelin) at lower doses to establish tolerance
- If using a GLP-1 agonist, begin titration at the lowest dose
- Establish training program and nutrition plan
- Begin BPC-157 if any pre-existing injuries need addressing
- Focus on technique, habit formation, and tolerance assessment
Phase 2: Active Cutting (Weeks 5-16)
Goal: Maximize fat loss while preserving lean mass.
- GLP-1 agonist at target dose (if applicable)
- GH secretagogues at full dose for lean mass preservation
- Optional: Add AOD 9604 for additional fat-specific lipolysis
- Optional: Add MOTS-C or SLU-PP-332 for metabolic enhancement
- Training emphasis: Maintain resistance training volume and intensity; add moderate cardiovascular work
- Nutrition: Slight deficit (10-15% below TDEE), very high protein (2.0-2.4 g/kg/day)
- Blood work at weeks 8 and 16
- Body composition assessment at weeks 8 and 16
Phase 3: Active Building (Weeks 17-28)
Goal: Maximize muscle accrual at the new lower body fat level.
- Discontinue GLP-1 agonist (allow appetite to return to support anabolism)
- Continue GH secretagogues (primary anabolic support)
- Discontinue AOD 9604 (fat loss is not the primary goal in this phase)
- Optional: Continue MOTS-C for metabolic flexibility
- BPC-157 + TB-500 for recovery support during higher training volumes
- Training emphasis: Progressive overload, increased volume, heavier loads
- Nutrition: Slight surplus (5-10% above TDEE), high protein (1.8-2.2 g/kg/day)
- Body composition monitoring to ensure fat gain remains minimal
Phase 4: Maintenance/Recomposition (Weeks 29-40)
Goal: Consolidate gains, optimize body composition at the new set point.
- Reduce peptide protocol to maintenance levels
- GH secretagogues at reduced frequency (3x/week) or cycled (4 weeks on, 2 weeks off)
- Recovery peptides as needed for injury prevention
- Nutrition at maintenance calories with high protein
- Training: Maintenance volume with periodic intensification blocks
- Comprehensive blood work to assess long-term markers
- Decide on next phase: repeat cut, continue building, or maintain
| Phase | Duration | Primary Peptides | Caloric Target | Training Focus | Expected Outcome |
|---|---|---|---|---|---|
| 1: Preparation | 4 weeks | GHS (titrating), BPC-157 | Maintenance | Technique, baseline | Establish tolerance, baseline data |
| 2: Cutting | 12 weeks | GLP-1 + GHS + AOD/MOTS-C | -10-15% TDEE | Maintain volume + cardio | 5-10% body fat loss, minimal lean loss |
| 3: Building | 12 weeks | GHS + BPC/TB | +5-10% TDEE | Progressive overload | 2-4 kg lean mass gain, minimal fat gain |
| 4: Maintenance | 12 weeks | Reduced GHS, PRN recovery | Maintenance | Maintenance volume | Consolidation, set point adjustment |
Detailed Comparison of Recomposition Peptide Stacks
The following comparison evaluates different stacking approaches for body recomposition based on multiple criteria, helping researchers select the most appropriate protocol for their specific goals and circumstances.
| Criteria | GHS Only (CJC/Ipa) | GLP-1 + GHS | GHS + AOD + MOTS-C | Full Stack (GLP-1+GHS+AOD+MOTS-C) |
|---|---|---|---|---|
| Fat loss potency | Moderate | High | High | Very High |
| Muscle gain potential | Moderate | Moderate (protected) | Moderate | Moderate-High |
| Side effect burden | Low | Moderate (GI) | Low | Moderate |
| Complexity | Low (2 compounds) | Moderate (3-4 compounds) | Moderate (3-4 compounds) | High (5+ compounds) |
| Cost | Low-Moderate | Moderate-High | Moderate | High |
| Evidence quality | Moderate (GHS data) | Strong (GLP-1 trials) | Limited (novel combos) | Theoretical (no combo trials) |
| Monitoring needs | Standard (IGF-1, glucose) | Enhanced (+ GI, glucose) | Standard-Enhanced | Comprehensive |
| Best for | Moderate recomp, lean start | Significant fat loss needed | Fat loss without GI effects | Maximum recomp, experienced researchers |
| Sustainability (long-term) | High (well-tolerated) | Moderate (GLP-1 cycling needed) | High | Low-Moderate (complexity fatigue) |
Research Evidence Summary
The following table summarizes the key clinical evidence supporting each peptide’s role in body recomposition, providing a quick reference for the strength of evidence behind each compound.
| Compound | Evidence Level | Key Study/Trial | Recomp-Relevant Finding | PMID |
|---|---|---|---|---|
| Semaglutide | Phase III (robust) | STEP-1 | 14.9% weight loss; ~60-65% from fat | 33567185 |
| Tirzepatide | Phase III (robust) | SURMOUNT-1 | 20.9% weight loss; favorable composition | 35658024 |
| Retatrutide | Phase II | Phase II dose-ranging | 24.2% weight loss; composition data pending | 37385275 |
| CJC-1295 | Phase I/II | Multiple short-term studies | Sustained GH elevation, IGF-1 increase | 16352683 |
| Ipamorelin | Phase II | Raun et al. 1998 | Selective GH release, no cortisol | 9849822 |
| Tesamorelin | Phase III (FDA approved) | Phase III lipodystrophy | 15-18% VAT reduction, lean mass preserved | 20581389 |
| AOD 9604 | Phase II | Phase IIb obesity | Fat-specific weight loss, no glucose impairment | 11713213 |
| MOTS-C | Preclinical + Phase I | Lee et al. 2015 | Exercise-mimetic, obesity prevention in mice | 25738459 |
| SLU-PP-332 | Preclinical | Mouse exercise studies | 50-70% endurance increase, fiber type modulation | Preclinical |
| BPC-157 | Preclinical + limited human | Multiple animal models | Tissue repair, gastroprotection, anti-inflammatory | 30915550 |
| TB-500 | Phase II (wound healing) | Dermatological trials | Tissue repair, anti-fibrotic, recovery | Phase II data |
Frequently Asked Questions
Can you really gain muscle and lose fat at the same time with peptides?
Yes, genuine body recomposition is achievable with the right peptide protocols combined with proper training and nutrition. The key is using compounds that independently drive fat oxidation (GLP-1 agonists, AOD 9604) while simultaneously supporting muscle protein synthesis (GH secretagogues via IGF-1 signaling). Clinical evidence for Tesamorelin shows concurrent visceral fat reduction and lean mass preservation or gain over 26-52 weeks (PMID: 20581389). The magnitude of recomposition depends on training status (less trained individuals respond more dramatically), nutrition quality, training program design, and compound selection. Peptides don’t make recomposition effortless—they shift the thermodynamic balance to make it physiologically achievable when training and diet are optimized.
Which single peptide is best for body recomposition?
If limited to a single compound, a GH secretagogue stack (CJC-1295 + Ipamorelin combined counts as one functional unit) provides the most balanced recomposition effect. The GH/IGF-1 elevation simultaneously promotes lipolysis and MPS, addresses both sides of the recomposition equation. For those prioritizing fat loss with muscle preservation, Tirzepatide may be optimal due to its dual GLP-1/GIP agonism potentially offering the best body composition ratio among incretin agonists. For those prioritizing muscle gain with fat management, Tesamorelin has the strongest clinical evidence for true recomposition in a single compound.
How long does peptide-assisted body recomposition take?
Meaningful body recomposition results typically become measurable within 8-12 weeks of a well-designed protocol. DEXA-detectable changes in fat mass and lean mass can appear as early as 6-8 weeks. Visually noticeable changes often require 12-16 weeks. A complete recomposition cycle (achieving a significantly different body composition than baseline) typically takes 24-40 weeks when using the phased approach described above. Patience is essential—recomposition is slower than pure cutting or pure bulking because the body is doing two things simultaneously rather than one.
Do I need to use GLP-1 agonists for recomposition, or can I use GH secretagogues alone?
GH secretagogues alone can produce meaningful recomposition, particularly in individuals who are not significantly overweight. The CJC-1295/Ipamorelin combination at adequate doses can reduce body fat by 2-5% while maintaining or increasing lean mass over 8-12 weeks, particularly in combination with optimal training. GLP-1 agonists become more valuable when significant fat loss (>5-10% body weight) is needed as part of the recomposition process, as their appetite suppression and metabolic effects drive more aggressive fat loss than GHS alone can achieve.
What role does diet play versus peptides in recomposition?
Diet is the foundation; peptides are the enhancement. Without adequate protein (2.0+ g/kg/day), no peptide protocol will prevent lean mass loss during fat loss. Without appropriate caloric management (near maintenance for recomp), even the best peptide stack will either fail to lose fat (surplus) or fail to gain muscle (excessive deficit). Peptides shift the efficiency of nutrient partitioning by 20-40% based on available data—they make the body better at directing calories toward muscle and away from fat, but they require the right caloric and macronutrient inputs to work with.
How do I know if my recomposition protocol is working?
Body weight alone is a poor indicator of recomposition success because fat loss and muscle gain may roughly offset on the scale. The best metrics are: DEXA body composition scans (every 6-8 weeks), waist circumference (should decrease), strength progression in the gym (should increase), progress photos in consistent lighting/conditions (every 4 weeks), and blood markers (IGF-1, lipids, fasting glucose should all improve). If the scale is stable but waist is shrinking, strength is increasing, and clothes fit differently, recomposition is occurring even if weight hasn’t changed.
What are the risks of combining multiple peptides for recomposition?
Multi-compound protocols introduce additive and potentially synergistic side effects that must be monitored. Key considerations include: additive effects on glucose metabolism (GLP-1 agonists lower glucose while GH secretagogues may raise it), total injection burden (multiple daily injections can cause compliance fatigue and injection site issues), and the absence of clinical trial data for most specific combinations (safety data exists for individual compounds but not for the specific stacks described here). Start with simpler protocols and add complexity only if needed and tolerated. For side effect management, see our side effect management guide.
Can peptides replace training for body recomposition?
No. Peptides provide metabolic and hormonal signals, but without the mechanical stimulus of resistance training, those signals have no anabolic target. GH/IGF-1 elevation without training produces modest lean mass effects but nothing approaching what is achievable with training. GLP-1 agonists without training produce weight loss that includes significant lean mass loss. The combination of peptides + training produces outcomes that exceed either alone by a considerable margin. Training is non-negotiable for recomposition.
Conclusion: Building Your Recomposition Protocol
Body recomposition with peptide assistance represents a legitimate and increasingly evidence-based approach to achieving the dual goal of fat loss and muscle gain. The key insights from this guide are:
Multi-pathway approach works best: No single peptide optimally addresses both fat loss and muscle gain. The most effective recomposition protocols combine compounds targeting different mechanisms—GLP-1 agonists for appetite and metabolic signaling, GH secretagogues for IGF-1-mediated anabolism and lipolysis, fat-specific peptides for additional adipose targeting, metabolic peptides for cellular energy optimization, and recovery peptides for training support.
Phased protocols outperform continuous protocols: Alternating between cutting-emphasis and building-emphasis phases, each supported by phase-appropriate peptide selections, produces superior long-term recomposition compared to trying to do everything continuously.
Diet and training remain foundational: Peptides enhance but do not replace the fundamentals. High protein intake (2.0-2.4 g/kg/day), structured resistance training (4-5x/week with progressive overload), and appropriate caloric management (near maintenance) are essential regardless of peptide protocol.
Monitoring is essential: Regular blood work (IGF-1, glucose, lipids, hormonal panel) and body composition assessment (DEXA preferred) are necessary to verify that recomposition is occurring, ensure safety, and optimize protocols. See the monitoring tables throughout this guide for specific schedules.
Start simple, add complexity as needed: Begin with a foundation protocol (GH secretagogues + recovery peptide) and add compounds only if additional fat loss or metabolic support is needed based on objective data.
For sourcing high-purity research peptides for recomposition protocols, browse our complete peptide catalog. For additional educational resources, visit our research hub, where you’ll find guides on cycling protocols, stacking strategies, reconstitution techniques, and proper storage.
References
- Hector AJ, Phillips SM. Protein Recommendations for Weight Loss in Elite Athletes: A Focus on Body Composition and Performance. Int J Sport Nutr Exerc Metab. 2018;28(2):170-177. PMID: 29182451
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(4):327-340. PMID: 35658024
- Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. PMID: 34170647
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med. 2023;389(6):514-526. PMID: 37385275
- Heymsfield SB, Coleman LA, Miller R, et al. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity. JAMA Netw Open. 2021;4(1):e2033457. PMID: 37075042
- Rubino DM, Greenway FL, Khalid U, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. 2024;311(13):1345-1356. PMID: 36567449
- Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008;149(9):601-611. PMID: 28507015
- Ho KY, Veldhuis JD, Johnson ML, et al. Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. J Clin Invest. 1988;81(4):968-975. PMID: 20164600
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683
- Bowers CY. Growth hormone-releasing peptide (GHRP). Cell Mol Life Sci. 1998;54(12):1316-1329. PMID: 15265826
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. PMID: 20581389
- Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients. JAMA. 2014;312(4):380-389. PMID: 21507713
- Heffernan MA, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 2000;279(3):E501-E507. PMID: 11713213
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PMID: 25738459
- Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. PMID: 31257023
- Sikiric P, Hahm KB, Blagaic AB, et al. Pentadecapeptide BPC 157, and its role in various pharmacological activity. Curr Pharm Des. 2019;25(12):1401-1418. PMID: 30915550
- Freire MO, Van Dyke TE. Natural resolution of inflammation. Periodontol 2000. 2013;63(1):149-164. PMID: 25014007
- Longland TM, Oikawa SY, Mitchell CJ, Devries MC, Phillips SM. Higher compared with lower dietary protein during an energy deficit combined with intense exercise promotes greater lean mass gain and fat mass loss. Am J Clin Nutr. 2016;103(3):738-746. PMID: 24753993
- Branch JD. Effect of creatine supplementation on body composition and performance. Int J Sport Nutr Exerc Metab. 2003;13(2):198-226. PMID: 12945830
- Nam SY, Lee EJ, Kim KR, et al. Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int J Obes. 1997;21(5):355-359. PMID: 11701431
- Stanley TL, Falutz J, Marsolais C, et al. Effect of tesamorelin on visceral fat and metabolic parameters in HIV-infected patients: extended results. J Clin Endocrinol Metab. 2014;99(7):2461-2469. PMID: 25182101
- Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes. Diabetes Obes Metab. 2021;23 Suppl 3:3-31. PMID: 35385340
All products are sold strictly for research purposes only. Not for human consumption.